Pneumococcal vaccine recombinant(GlaxoSmithKline Plc)(Pneumococcal vaccine recombinant(GlaxoSmithKline Plc))

概要

基本信息

药物类型

预防性疫苗

别名

Pneumococcal vaccine recombinant、S. pneumoniae adult vaccine

+ [3]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染耳鼻咽喉疾病

在研适应症-

非在研适应症

耳感染中耳炎链球菌感染

原研机构

GSK Plc

在研机构-

非在研机构

GSK Plc

权益机构-

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

6

项与 Pneumococcal vaccine recombinant(GlaxoSmithKline Plc) 相关的临床试验

NCT01545375

/ Completed临床2期

Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants

The purpose of this study is to 1) demonstrate the protective efficacy against acute otitis media (AOM), 2) assess safety of the GlaxoSmithKline (GSK) Biologicals' pneumococcal vaccine GSK2189242A in Native American infants aged less than 24 months, living in the southwestern US, in and around the Navajo and White Mountain Apache reservations, and 3) evaluate the impact on acute lower respiratory tract infections (ALRI) up to the second year of life.

开始日期2012-05-21

申办/合作机构

GSK Plc

NCT01262872

/ Completed临床2期

Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety and Immunogenicity When Co-administered With Routine EPI Vaccines in Infants Following Safety Assessment in Children Aged 2-4 Years in The Gambia

This study will assess the impact on nasopharyngeal carriage, safety and immunogenicity of GSK Biologicals' pneumococcal vaccine 2189242A given as a 3-dose vaccination course and co-administered with other routine paediatric vaccines in infants in The Gambia. Two formulations containing different doses of pneumococcal antigen and two different schedules will be tested in infants.

开始日期2011-02-09

申办/合作机构

GSK Plc

[+3]

NCT01204658

/ Completed临床2期

Safety, Reactogenicity & Immunogenicity of GSK Biologicals' Pneumococcal Vaccine 2189242A When Co-administered With DTPa-HBV-IPV/Hib Vaccine in Healthy Infants

This study will assess the safety, reactogenicity and immunogenicity of two formulations of GSK Biologicals' pneumococcal vaccine 2189242A given as a 3-dose primary vaccination course during the first 6 months of life followed by a booster dose at 12-15 months of age and co-administered with DTPa-HBV-IPV/Hib vaccine.

开始日期2010-09-27

申办/合作机构

GSK Plc

100 项与 Pneumococcal vaccine recombinant(GlaxoSmithKline Plc) 相关的临床结果

登录后查看更多信息

100 项与 Pneumococcal vaccine recombinant(GlaxoSmithKline Plc) 相关的转化医学

登录后查看更多信息

100 项与 Pneumococcal vaccine recombinant(GlaxoSmithKline Plc) 相关的专利（医药）

登录后查看更多信息

21

项与 Pneumococcal vaccine recombinant(GlaxoSmithKline Plc) 相关的文献（医药）

2023-09-01·Molecular Immunology

ΔA146Ply-HA stem protein immunization protects mice against influenza A virus infection and co-infection with Streptococcus pneumoniae

Article

作者: Xu, Wenlong ; Li, Lian ; Wang, Hanyi ; Yang, Rui ; Zhang, Xuemei ; Yuan, Yuan ; Yin, Yibing ; Xiao, Jiangming ; Guo, Ting

Influenza virus (IV) is a common pathogen affecting the upper respiratory tract, that causes various diseases. Secondary bacterial pneumonia is a common complication and a major cause of death in influenza patients. Streptococcus pneumoniae (S. pneumoniae) is the predominant co-infected bacteria in the pandemic, which colonizes healthy people but can cause diseases in immunocompromised individuals. Vaccination is a crucial strategy for avoiding infection, however, no universal influenza vaccine (UIV) that is resistant to multiple influenza viruses is available. Despite its limited immunogenicity, the hemagglutinin (HA) stem is a candidate peptide for UIV. ΔA146Ply (pneumolysin with a single deletion of A146) not only retains the Toll-like receptor 4 agonist effect but also is a potential vaccine adjuvant and a candidate protein for the S. pneumoniae vaccine. We constructed the fusion protein ΔA146Ply-HA stem and studied its immunoprotective effect in mice infection models. The results showed that intramuscular immunization of ΔA146Ply-HA stem without adjuvant could induce specific antibodies against HA stem and specific CD4⁺ T and CD8⁺ T cellular immunity in BALB/c and C57BL/6 mice, which could improve the survival rate of mice infected with IAV and co-infected with S. pneumoniae, but the protective effect on BALB/c mice was better than that on C57BL/6 mice. ΔA146Ply-HA stem serum antibody could protect BALB/c and C57BL/6 mice from IAV, and recognized HA polypeptides of H3N2, H5N1, H7N9, and H9N2 viruses. Moreover, ΔA146Ply-HA stem intramuscular immunization had a high safety profile with no obvious toxic side effects. The results indicated that coupling ΔA146Ply with influenza protein as a vaccine was a safe and effective strategy against the IV and secondary S. pneumoniae infection.

2023-01-01·Frontiers in molecular biosciences

Integrated immunoinformatics and subtractive proteomics approach for multi-epitope vaccine designing to combat S. pneumoniae TIGR4.

Article

作者: Faidah, Hani ; Jalal, Naif A ; Qusty, Naeem F ; Darwish, Abdulla ; Ashgar, Sami S ; Janahi, Essam M ; Haque, Shafiul ; Bantun, Farkad

Streptococcus pneumoniae is one of the major precarious pathogens accountable for over 1.2 million fatalities annually. The key drivers for pneumococcal vaccine development involve high morbidity and mortality in over one million cases, especially in very young children and the elderly. In this study, immunoinformatics was integrated with subtractive proteomics to find antigenic proteins for designing a multi-epitope vaccine against S. pneumoniae. As prospective vaccine targets, the developed pipeline identified two antigenic proteins, i.e., penicillin-binding protein and ATP synthase subunit. Several immunoinformatics and bioinformatics resources were used to forecast T- and B-cell epitopes from specific proteins. By employing a mixture of five cytotoxic T-cell lymphocytes, six helper T-cell lymphocytes, and seven linear B-cell lymphocyte epitopes, a 392 amino acid-long vaccine was designed. To enhance immune responses, the designed vaccine was coupled with a cholera enterotoxin subunit B adjuvant. The designed vaccine was highly antigenic, non-allergenic, and stable for human usage. The stability of the vaccine with toll-like receptor-4 was evaluated by molecular docking and molecular dynamic simulation. In addition, immunological simulation was performed to test its real-world potency. The vaccine codon was then cloned in silico. Overall, this study paves the way for the development of a multi-epitope S. pneumoniae vaccine under laboratory conditions. Furthermore, the current findings warrant for the experimental validation of the final multi-epitope vaccine construct to demonstrate its immunological reinforcing capability and clinical applicability.

2021-04-15·The Journal of Immunology2区 · 医学

Glycolipid-Containing Nanoparticle Vaccine Engages Invariant NKT Cells to Enhance Humoral Protection against Systemic Bacterial Infection but Abrogates T-Independent Vaccine Responses

2区 · 医学

Article

作者: Nash, Kelly ; Vincent, Brandy K ; Yates, Jennifer L ; Vomhof-Dekrey, Emilie ; Angel, Daniel ; Weyers, Amanda ; Durham, Olivia ; Dudley, Elizabeth ; Leadbetter, Elizabeth A ; Shipp, Devon ; Alam, Noran ; Fromme, Rachel ; Mesa, Chloe ; Mohrs, Katya ; Salas, Briana ; Miao, Jianjun ; Serrata, Adriana ; Linhardt, Robert J ; Laughlin, Mitchell ; Lanthier, Paula A ; Shute, Travis ; Amiel, Eyal

AbstractCD4+ T cells enable the critical B cell humoral immune protection afforded by most effective vaccines. We and others have recently identified an alternative source of help for B cells in mice, invariant NK T (iNKT) cells. iNKT cells are innate glycolipid-specific T cells restricted to the nonpolymorphic Ag-presenting molecule CD1d. As such, iNKT cells respond to glycolipids equally well in all people, making them an appealing adjuvant for universal vaccines. We tested the potential for the iNKT glycolipid agonist, α-galactosylceramide (αGC), to serve as an adjuvant for a known human protective epitope by creating a nanoparticle that delivers αGC plus antigenic polysaccharides from Streptococcus pneumoniae. αGC-embedded nanoparticles activate murine iNKT cells and B cells in vitro and in vivo, facilitate significant dose sparing, and avoid iNKT anergy. Nanoparticles containing αGC plus S. pneumoniae polysaccharides elicits robust IgM and IgG in vivo and protect mice against lethal systemic S. pneumoniae. However, codelivery of αGC via nanoparticles actually eliminated Ab protection elicited by a T-independent S. pneumoniae vaccine. This is consistent with previous studies demonstrating iNKT cell help for B cells following acute activation, but negative regulation of B cells during chronic inflammation. αGC-containing nanoparticles represent a viable platform for broadly efficacious vaccines against deadly human pathogens, but their potential for eliminating B cells under certain conditions suggests further clarity on iNKT cell interactions with B cells is warranted.

100 项与 Pneumococcal vaccine recombinant(GlaxoSmithKline Plc) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
耳感染	临床2期	美国	GSK Plc	2012-05-21
中耳炎	临床2期	美国	GSK Plc	2012-05-21
链球菌感染	临床2期	比利时	GSK Plc	2009-05-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00985751 (CTgov)	临床2期	链球菌感染	257	Synflorix (Synflorix Group)	觸繭齋簾製餘廠顧築窪(膚齋齋蓋窪夢繭顧醖糧) = 鏇醖構衊遞齋顧範襯遞醖觸觸餘製艱鑰製醖窪 (齋鏇鹹淵遞餘鹽壓廠憲, 憲膚鬱繭襯選觸糧簾獵 ~ 衊鏇網憲艱鏇獵淵餘願) 更多	-	2017-10-06
				Synflorix+GSK 2189242A (Synflorix/GSK 2189242A Group)	觸繭齋簾製餘廠顧築窪(膚齋齋蓋窪夢繭顧醖糧) = 積襯積鹽構壓繭觸夢夢醖觸觸餘製艱鑰製醖窪 (齋鏇鹹淵遞餘鹽壓廠憲, 鹹網淵艱壓積願醖蓋築 ~ 網築觸憲築繭範鏇齋鏇)
NCT01545375 (CTgov)	临床2期	链球菌感染 \| 耳感染 \| 中耳炎	1,806	Pneumococcal vaccine GSK2189242A+PedvaxHIB®+Prevnar 13® (dPly-PhtD Group)	餘憲鬱選選鑰簾淵齋廠(艱觸鹽蓋膚簾艱襯膚繭) = 醖遞憲顧憲廠願膚夢範鹽窪獵製網壓艱範網願 (憲淵艱襯糧醖憲餘齋齋, 鹽積膚淵窪壓齋憲繭觸 ~ 構願襯夢顧艱蓋壓淵餘) 更多	-	2017-09-12
				Placebo+PedvaxHIB®+Prevnar 13® (Control Group)	餘憲鬱選選鑰簾淵齋廠(艱觸鹽蓋膚簾艱襯膚繭) = 觸獵廠願襯襯膚願鑰範鹽窪獵製網壓艱範網願 (憲淵艱襯糧醖憲餘齋齋, 壓構鏇鹹簾鏇築簾選願 ~ 鹽壓鏇顧艱醖蓋範顧壓) 更多
NCT00896064 (CTgov)	临床2期	链球菌感染	43	GSK2189242A (GSK2189242A Formulation 1 Group)	(遞淵廠顧艱艱鑰獵憲鏇) = 選網願觸鏇顧窪鹹壓餘簾願獵獵選糧獵夢鹹遞 (夢齋廠遞繭鏇膚夢廠艱, 遞鬱願鏇醖淵獵憲觸鹹 ~ 構壓簾蓋構選廠衊繭憲) 更多	-	2017-07-19
				GSK2189242A (GSK2189242A Formulation 2 Group)	(遞淵廠顧艱艱鑰獵憲鏇) = 築鑰願鑰築築廠鏇繭餘簾願獵獵選糧獵夢鹹遞 (夢齋廠遞繭鏇膚夢廠艱, 製遞壓鑰憲觸窪襯製簾 ~ 蓋鏇醖醖獵衊繭蓋壓廠) 更多
NCT01204658 (CTgov)	临床2期	链球菌感染	576	DTPa-HBV-IPV+Infanrix Hexa+Pneumococcal vaccine GSK 2189242A (LD formulation 1)+Hib (10PP-LD/Infanrix Hexa Group)	築構醖鑰選廠網膚簾顧(醖顧願憲廠醖鏇鏇願構) = 壓選鑰襯鹽膚繭積製製夢壓鹹構餘壓選淵醖觸 (憲網遞膚選淵齋顧網製, 夢襯鏇廠觸繭襯鑰網繭 ~ 構鏇築夢淵鹽簾醖壓選) 更多	-	2016-09-28
				DTPa-HBV-IPV+Infanrix Hexa+Pneumococcal vaccine GSK 2189242A (HD formulation 2)+Hib (10PP-HD/Infanrix Hexa Group)	築構醖鑰選廠網膚簾顧(醖顧願憲廠醖鏇鏇願構) = 簾觸選觸艱蓋繭觸艱廠夢壓鹹構餘壓選淵醖觸 (憲網遞膚選淵齋顧網製, 鑰簾衊蓋願壓鬱獵顧築 ~ 醖遞遞齋獵窪繭鬱餘糧) 更多